| PRODUCTSSERVICESCOMPANYCONTACTFAQ |
|
Description: is a HIF-1 inhibitor with potential for use as both an analytic tool and a therapeutic agent
| 1. | Uranchimeg, Badarch: 1 article (02/2007) |
| 2. | Stephen, Andrew G: 1 article (02/2007) |
| 3. | Cardellina, John H: 1 article (02/2007) |
| 4. | Creighton-Gutteridge, Mark: 1 article (02/2007) |
| 5. | Melillo, Giovanni: 1 article (02/2007) |
| 6. | Rapisarda, Annamaria: 1 article (02/2007) |
| 7. | Denny, William A: 1 article (02/2007) |
| 8. | Shoemaker, Robert H: 1 article (02/2007) |
| 9. | Hite, Karen: 1 article (02/2007) |
| 1. | Neoplasms (Cancer)
02/01/2007
- "Furthermore, although NSC 644221 induced p21 expression, gammaH2A.X, and G2-M arrest in the majority of cell lines tested, it only inhibited HIF-1alpha in a distinct subset of cells, raising the possibility of pathway-specific "resistance" to HIF-1 inhibition in cancer cells. "
Order ALL the reference details at left... |
| 2. | Anoxia (Hypoxia)
02/01/2007
- "Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221."
Order ALL the reference details at left... |
| 1. | Type II DNA Topoisomerases (Topoisomerase II)
|
CureHunter Patient-Physician Summary Reports collect in one document all the
medications ever reported in the US National Library of Medicine—1949 to the present—to
be effective against your target disease.
CureHunter research summary reports will vary in length from 25 to 250 pages.
Analytic charts allow you and your physicians to see at a glance your
medication options—including new, promising, off-label and experimental
all rated for clinical efficacy.
| Price: | $24.00
& Delivery via
PDF download
updates for 1 year |
| Price: | $490.00
access via web interface 1 year subscription |
| Price: | $45.00
access via "curehunter.com/m" 1 year subscription |